Literature DB >> 23032413

Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study.

Giordano Madeddu1, Barbara Menzaghi, Elena Ricci, Laura Carenzi, Canio Martinelli, Antonio di Biagio, Giustino Parruti, Giancarlo Orofino, Maria S Mura, Paolo Bonfanti.   

Abstract

Central nervous system (CNS) symptoms have been reported in clinical trials and case reports in patients receiving raltegravir. We investigated CNS symptoms in 453 HIV-infected patients. Of these 47 (10.4%) developed at least one drug-related CNS symptom. Predictors of CNS symptoms were concomitant therapy with tenofovir or with proton pump inhibitors that can increase raltegravir concentration. Thus, our data suggest a possible correlation between high raltegravir plasma concentrations and CNS symptoms, and therefore their monitoring in clinical practice.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23032413     DOI： 10.1097/QAD.0b013e32835aa141

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  12 in total

1.  Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients.

Authors:  Massimiliano Fabbiani; Nicoletta Ciccarelli; Valeria Castelli; Alessandro Soria; Alberto Borghetti; Elisa Colella; Davide Moschese; Manuela Valsecchi; Arianna Emiliozzi; Andrea Gori; Andrea De Luca; Alessandra Bandera; Simona Di Giambenedetto
Journal:  J Neurovirol       Date:  2019-07-07       Impact factor: 2.643

2.  Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV.

Authors:  Leah H Rubin; Jane A O'Halloran; Dionna W Williams; Yuliang Li; Kathryn C Fitzgerald; Raha Dastgheyb; Alexandra L Damron; Pauline M Maki; Amanda B Spence; Anjali Sharma; Deborah R Gustafson; Joel Milam; Kathleen M Weber; Adaora A Adimora; Igho Ofotokun; Margaret A Fischl; Deborah Konkle-Parker; Yanxun Xu
Journal:  J Neuroimmune Pharmacol       Date:  2022-02-17       Impact factor: 7.285

3.  Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV.

Authors:  Dionna W Williams; Yuliang Li; Yanxun Xu; Leah H Rubin; Raha Dastgheyb; Kathryn C Fitzgerald; Pauline M Maki; Amanda B Spence; Deborah R Gustafson; Joel Milam; Anjali Sharma; Adaora A Adimora; Igho Ofotokun; Margaret A Fischl; Deborah Konkle-Parker; Kathleen M Weber
Journal:  J Neuroimmune Pharmacol       Date:  2020-01-13       Impact factor: 7.285

4.  Class-Based Antiretroviral Exposure and Cognition Among Women Living with HIV.

Authors:  Amanda Blair Spence; Chenglong Liu; Leah Rubin; Bradley Aouizerat; David Eugene Vance; Hector Bolivar; Cecile Delille Lahiri; Adaora A Adimora; Kathleen Weber; Deborah Gustafson; Oluwakemi Sosanya; Raymond Scott Turner; Seble Kassaye
Journal:  AIDS Res Hum Retroviruses       Date:  2022-03-02       Impact factor: 1.723

5.  Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV.

Authors:  Asante R Kamkwalala; Kunbo Wang; Yanxun Xu; Leah H Rubin; Jane O'Halloran; Dionna W Williams; Raha Dastgheyb; Kathryn C Fitzgerald; Amanda B Spence; Pauline M Maki; Deborah R Gustafson; Joel Milam; Anjali Sharma; Kathleen M Weber; Adaora A Adimora; Igho Ofotokun; Anandi N Sheth; Cecile D Lahiri; Margaret A Fischl; Deborah Konkle-Parker
Journal:  AIDS Behav       Date:  2021-01

Review 6.  Long-term efficacy and safety of raltegravir in the management of HIV infection.

Authors:  Michelle D Liedtke; C Ryan Tomlin; Staci M Lockhart; Misty M Miller; R Chris Rathbun
Journal:  Infect Drug Resist       Date:  2014-03-18       Impact factor: 4.003

7.  Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.

Authors:  Leïla Belkhir; Carole Seguin-Devaux; Laure Elens; Caroline Pauly; Nicolas Gengler; Serge Schneider; Jean Ruelle; Vincent Haufroid; Bernard Vandercam
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

8.  Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance.

Authors:  Naho Kuroishi; Asuka Watananbe; Ryuta Sakuma; Daniel J Ruzicka; Mitsuyoshi Hara
Journal:  PLoS One       Date:  2019-01-09       Impact factor: 3.240

9.  Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV.

Authors:  Victor G Valcour; Serena S Spudich; Napapon Sailasuta; Nittaya Phanuphak; Sukalaya Lerdlum; James L K Fletcher; Eugene D M B Kroon; Linda L Jagodzinski; Isabel E Allen; Collin L Adams; Peeriya Prueksakaew; Bonnie M Slike; Joanna M Hellmuth; Jerome H Kim; Jintanat Ananworanich
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

10.  Associations between Antiretrovirals and Cognitive Function in Women with HIV.

Authors:  Leah H Rubin; Yuliang Li; Yanxun Xu; Dionna W Williams; Kathryn C Fitzgerald; Raha Dastgheyb; Amanda B Spence; Pauline M Maki; Anjali Sharma; Deborah R Gustafson; Joel Milam; Kathleen M Weber; Adaora A Adimora; Norman J Haughey; Igho Ofotokun; Margaret A Fischl; Deborah Konkle-Parker
Journal:  J Neuroimmune Pharmacol       Date:  2020-03-24       Impact factor: 7.285
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.